R&D/Clinical Trials

A look at the renewed efforts of biopharma companies in exploring age-old substances to treat mental health conditions and more, minus the negative effects.

Opportunity remains despite regulatory and access obstacles.

Recommendations for controlling spend.

Masahide Goto outlines the world of the Astellas Institute for Regenerative Medicine (AIRM), which serves as the company’s global hub for regenerative medicine and cell therapy research and manufacturing in ophthalmology and other therapeutic areas that have few or no available treatment options.

New technology serves as reminder for the appropriate uses of CRISPR.

Significant challenges still lie ahead, but several specialists and a plethora of new technologies are well positioned to gather and analyze the evidence needed for diagnosing and treating rare diseases, writes Catherine Tak Piech.

Government-led programs aim to attract scientists and offer resources to growing industry.

Oncology and rare disease are ready to reap the benefits of COVID drug development.

Growing evidence supports psychoactive substances can successfully treat mental issues.

Our annual report takes a look at pharma’s current investment in drug development, which this year demonstrates a focus on five important therapeutic areas of interest—Alzheimer’s disease, ophthalmology, NASH, anti-infectives, and opioids.

Practices to ensure accuracy in selected datasets.

Having proved its efficacy against COVID-19, mRNA technology is positioned to combat another insidious human adversary: cancer.

Leveraging RWD can lessen the strain normally put on investigators and sites.

COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.

aTyr Pharma’s Dr. Sanjay S. Shukla talks about how his background in biostatistics, informatics and medicine is helping him and his team of researchers and scientists develop meaningful new medicines in a novel area of immunobiology, by looking at pathways where other drugs may have failed.

MIDD can pave new road for drug development.

Mark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.

With a background in pharma and biotech, ImmunoGen president and CEO Mark Enyedy discusses his dedication to oncology and the lessons he’s learned along the way.

AstraZeneca’s Mina Makar and Amgen’s Kave Niksefat talk about how the two companies worked together to develop the new asthma treatment, tezepelumab.

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.

With technological advancements in affinity tuning and real-time tracking of CAR-T cells, the hope is that CAR-T therapy can be effectively applied to treating solid tumors, improve patient outcomes, and avoid the toxicities seen with certain treatments in the clinic.

How Gilead readied remdesivir for the COVID challenge.

Inside Regeneron’s monoclonal antibody development to treat COVID.

Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.

Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.